Bausch Health Companies Inc. (TSE:BHC – Get Free Report)’s share price dropped 0.7% during trading on Friday. The stock traded as low as C$8.69 and last traded at C$9.03. 407,227 shares changed hands during mid-day trading, a decline of 24% from the average daily volume of 537,914 shares. The stock had previously closed at C$9.09.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group upgraded shares of Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 22nd. Three analysts have rated the stock with a Hold rating. According to MarketBeat, the company presently has a consensus rating of “Hold”.
Get Our Latest Stock Report on BHC
Bausch Health Companies Trading Down 0.7%
The stock has a market cap of C$3.38 billion, a P/E ratio of -3.07, a PEG ratio of 0.21 and a beta of 0.82. The firm’s fifty day moving average price is C$8.66 and its two-hundred day moving average price is C$7.86. The company has a debt-to-equity ratio of -1,173.29, a current ratio of 1.44 and a quick ratio of 0.58.
Bausch Health Companies (TSE:BHC – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported C$1.79 earnings per share (EPS) for the quarter. Bausch Health Companies had a positive return on equity of 87.57% and a negative net margin of 12.02%. The company had revenue of C$4.05 billion for the quarter. As a group, equities research analysts forecast that Bausch Health Companies Inc. will post 5.55 EPS for the current year.
Bausch Health Companies Company Profile
Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Read More
- Five stocks we like better than Bausch Health Companies
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
